Date : 7-8 May 2015
Location : London (UK)
View the link21 October 2014
- 21 October 2014
Paris, France – 16 April 2015 Microbiome sets off a rush among developers Pierre Belichard, CEO of Enterome, interviewed...16 April 2015
Paris, France – 19 March 2015 Enterome will be present at the International Human Microbiome Congress in Luxembourg, 31...19 March 2015
Who we are
Measurement and modulation of the gut microbiome in health and disease presents the opportunity to impact medicine in an entirely new and unexplored way.
Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. Opening up a new field of therapeutic targets discovery in the microbiome and allowing the innovative repositioning of existing compounds targeting this new organ.